Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Clinical Medical College, Hebei University, Baoding, 071002, Hebei, China.
J Nanobiotechnology. 2024 May 12;22(1):243. doi: 10.1186/s12951-024-02486-5.
Hepatocellular carcinoma (HCC) represents one of the deadliest cancers globally, making the search for more effective diagnostic and therapeutic approaches particularly crucial. Aptamer-functionalized nanomaterials (AFNs), an innovative nanotechnology, have paved new pathways for the targeted diagnosis and treatment of HCC. Initially, we outline the epidemiological background of HCC and the current therapeutic challenges. Subsequently, we explore in detail how AFNs enhance diagnostic and therapeutic efficiency and reduce side effects through the specific targeting of HCC cells and the optimization of drug delivery. Furthermore, we address the challenges faced by AFNs in clinical applications and future research directions, with a particular focus on enhancing their biocompatibility and assessing long-term effects. In summary, AFNs represent an avant-garde therapeutic approach, opening new avenues and possibilities for the diagnosis and treatment of HCC.
肝细胞癌（HCC）是全球最致命的癌症之一，因此寻找更有效的诊断和治疗方法尤为关键。适体功能化纳米材料（AFNs）作为一种创新的纳米技术，为 HCC 的靶向诊断和治疗开辟了新途径。首先，我们概述了 HCC 的流行病学背景和当前的治疗挑战。随后，我们详细探讨了 AFNs 如何通过 HCC 细胞的特异性靶向和药物输送的优化来提高诊断和治疗效率并降低副作用。此外，我们还讨论了 AFNs 在临床应用中面临的挑战和未来的研究方向，特别关注增强其生物相容性和评估长期效果。总之，AFNs 代表了一种先进的治疗方法，为 HCC 的诊断和治疗开辟了新的途径和可能性。
